Adgyl Lifesciences offers comprehensive In Vivo Pharmacology and efficacy studies in several therapeutic areas in GLP and non-GLP for drug discovery needs and regulatory submissions. The studies are well supported by requisite histopathology, immunohistochemistry, clinical biochemistry, biomarker (qPCR, cytokines by FACS/ELISA, Western Blot, immune-phenotyping using FACS). The GLP Bioanalysis and Formulation analysis are also performed.
Adgyl Lifescience scientists possess 20 plus years of in vivo pharmacology drug discovery experience to conduct efficacy studies for multiple therapeutic areas, in-house validated 100 plus models on board, rich surgical skills and model development skills. New model may be developed as per sponsors needs. Validated models as presented as follows:
The models are supported by strong expertise in ex vivo assays, histopathology, and PD marker studies
Metabolic Disease – Multiple animal models for the assessment of in vivo metabolic profile, in vivo cardiovascular profile and ex vivo studies
Gastrointestinal Disease – Interaction studies of pharmacological modulators using intestinal and colonic explants and sections, isolated fundus strips; multiple animal models including DSS-induced ulcerative colitis, TNBS-induced colitis, GI motility studies, peptic ulcers, etc.